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DNA methylation is an epigenetic mark that is essential for many biological
processes and is linked to diseases such as cancer. Methylation is usually associated
with transcriptional silencing, but new research has challenged this model. Both
transcriptional activation and repression have recently been found to be associated
with DNA methylation in a context-specific manner. How DNA methylation patterns
are interpreted into different functional output remains poorly understood. One
mechanism involves the protein ‘readers’ of methylation, which includes the methyl-
CpG binding domain (MBD) family of proteins. This review examines the molecular
and biological functions of MBD2, which binds to CpG methylation and is an
integral part of the nucleosome remodeling and histone deacetylation (NuRD) complex.
MBD2 has been linked to immune system function and tumorigenesis, yet little is
known about its functions in vivo. Recent studies have found the MBD2 protein is
ubiquitously expressed, with relatively high levels in the lung, liver, and colon. Mbd2
null mice surprisingly show relatively mild phenotypes compared to mice with loss
of function of other MBD proteins. This evidence has previously been interpreted as
functional redundancy between the MBD proteins. Here, we examine and contextualize
research that suggests MBD2 has unique properties and functions among the MBD
proteins. These functions translate to recently described roles in the development and
differentiation of multiple cell lineages, including pluripotent stem cells and various cell
types of the immune system, as well as in tumorigenesis. We also consider possible
models for the dynamic interactions between MBD2 and NuRD in different tissues
in vivo. The functions of MBD2 may have direct therapeutic implications for several
areas of human disease, including autoimmune conditions and cancer, in addition to
providing insights into the actions of NuRD and chromatin regulation.
Keywords: methyl-CpG binding domain protein, MBD2, MBD3, DNA methylation, nucleosome remodeling and
histone deacetylation complex (NuRD), chromatin, mouse genetics, transcription regulation
INTRODUCTION
DNA Methylation and Its Readers
DNA methylation is a chemical epigenetic modification that is essential for mammalian viability
and development. DNA methylation at CpG dinucleotides (mCG) has historically been associated
with stable gene repression; however, recent advances have revealed a complex role for DNA
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methylation in regards to its dynamic turnover, cell type-specific
distribution patterns, and effect on transcriptional regulation
(Suzuki and Bird, 2008; Smith and Meissner, 2013). DNA
methylation is also found outside of the CpG context (mCH),
particularly in embryonic stem cells (ESCs) and brain tissues
(Lister et al., 2009, 2013; Guo et al., 2014; Schultz et al.,
2015). While mCG is the most abundant modification, mCH
is detected at significantly lower frequencies compared to mCG
in non-neuronal tissues. The oxidized form of methylcytosine,
hydroxymethylation (hmC), is particularly enriched in ESCs and
the brain (Lister et al., 2009, 2013; Guo et al., 2014; Schultz et al.,
2015).
DNA methylation, particularly in the CpG context, is
intimately linked to histone modifications, formation of
heterochromatin, and transcription factor recruitment. Together
these mechanisms comprise the chromatin state and direct
gene expression programs. The genomic distributions of these
modifications are developmentally dynamic and cell type-
specific, but the mechanisms that direct the interpretation of
these patterns to affect specific gene expression programs have
yet to be fully determined. It has recently been found that
DNA methylation affects transcriptional regulation differently
depending on the genomic context. For example, mCG at
promoters is associated with transcriptional repression, while
the same mark in gene bodies is associated with high levels
of gene transcription (Schübeler, 2015). It is critical to gain
further understanding of the mechanisms of DNA methylation
in transcriptional regulation because these findings will aid
in our elucidation of other biological processes, including the
differentiation of pluripotent cells, neuronal development and
function, and tumorigenesis, among many others.
DNA methylation can directly influence transcription by
affecting how and where protein factors bind to DNA.
Transcription factors can be repelled by methylation at
promoters which leads to gene silencing (Blattler and Farnham,
2013; Domcke et al., 2015), but can also bind to specific
methylated sequences in association with active transcription
(Figures 1A–C; Spruijt and Vermeulen, 2014). DNA methylation
can also indirectly guide transcription through the specific
binding of several classes of proteins referred to as ‘readers’
of CpG methylation, which can then recruit other chromatin-
modifying proteins to DNA (Spruijt et al., 2013). Here, we focus
on the methyl-CpG binding domain (MBD) family of ‘reader’
proteins (Hendrich and Bird, 1998).
The MBD proteins are a key component of epigenetic
regulation as they act at the intersection of several critical
mechanisms that affect transcriptional regulation. The MBD
proteins may induce transcriptional silencing by blocking
transcription or other protein factors from binding to DNA
(Figure 1D), or by inducing chromatin remodeling through their
binding partners (Nan et al., 1998). However, there is evidence
that these proteins are also bound at actively transcribed genes
in promoters or intragenic sites, although the effect of this
binding on transcriptional regulation is not fully understood
(Baubec et al., 2013; Spruijt et al., 2013; Figures 1E,F). This and
other new evidence shows that the MBD proteins are dynamic
readers of methylation beyond their originally proposed roles
as transcriptional repressors, and therefore are essential to our
understanding of epigenetic processes. Despite many biochemical
and genetic studies on the MBD proteins, the precise functions of
these proteins in vivo are yet to be fully investigated.
The MBD Protein Family
The functions of the MBD family of proteins have been of
great interest because these proteins have been genetically linked
to disease in humans. The MBD family represents a group of
proteins that generally act as mediators between methylation,
primarily in the CpG context, and other chromatin and histone
modifying protein complexes (Du et al., 2015). The MBD protein
family consists of MeCP2 and MBD1-6 (Figure 2). Despite
the name, not all members of this family bind to mCG with
exclusivity, or at all. Instead the MBD proteins have distinct
DNA-binding properties and other functional domains that may
contribute to their respective functions. MeCP2, MBD1 and
MBD2 bind to DNA in a mCG-density dependent manner via
the MBD and associate with co-repressor and other protein
complexes through their transcriptional repression domains
(TRDs; Nan et al., 1998; Ng et al., 1999; Fujita et al., 2000;
Feng and Zhang, 2001; Baubec et al., 2013). MBD1 can bind to
unmodified cytosine through its CxxC-type zinc finger domains
in addition to recognizing mCG through its MBD (Jørgensen
et al., 2004). MBD3 has a point mutation in the MBD domain that
abolishes its selective binding to mCG, and instead binds with
low affinity to unmodified cytosine, mCG, and hmC (Hashimoto
et al., 2012a; Spruijt et al., 2013). MBD4 binds to methylated
DNA and has DNA glycosylase activity that is unique in the MBD
family (Hashimoto et al., 2012b). The most recently described
MBD proteins, MBD5 and MBD6, are localized at pericentric
heterochromatin but do not specifically bind methylated DNA
(Laget et al., 2010).
In this review, we examine and contextualize research on
MBD2. This MBD protein is highly conserved, ubiquitously
expressed, and interacts with the nucleosome remodeling and
histone deacetylation (NuRD) complex (Hendrich and Bird,
1998; Hendrich et al., 2001; Hendrich and Tweedie, 2003; Wood
et al., 2016). Surprisingly, Mbd2 null mice show only mild
phenotypes compared to mice with loss of function of other
MBD proteins (Hendrich et al., 2001; Wood et al., 2016). One
proposed explanation for this discrepancy is that some amount
of functional redundancy exists among the MBD proteins
(Baubec and Schübeler, 2014). However, biochemical and genetic
evidence suggests that MBD2 has unique functions that have
recently been shown to contribute to transcriptional regulation
in pluripotent cells, immune lymphocytes, and in tumorigenesis.
Here, we address the molecular functions of MBD2, roles for
MBD2 in biological processes and human disease, and models of
MBD2 interaction with the NuRD complex.
MBD2 MOLECULAR FUNCTIONS
MBD2 Gene and Protein Structure
Mammalian MBD2 was identified in a search for proteins
containing the conserved MBD (Hendrich and Bird, 1998).
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FIGURE 1 | Models of 5-methylcytosine affecting transcription factor recruitment. (A) The binding of transcription factors at hypomethylated regulatory
regions drives transcriptional activation. (B) Activating transcription factors are blocked from binding hypermethylated regulatory regions, inducing transcriptional
silencing. (C) Methylation-specific transcription factors bind hypermethylated regulatory regions to activate transcription. (D) Methyl-CpG binding domain (MBD)
proteins can bind hypermethylated regions and block transcription factor binding to induce transcriptional silencing. MBD proteins bind to actively transcribed genes
at intragenic (E) or promoter (F) sites, but the effect of this binding on transcriptional regulation is unclear.
FIGURE 2 | The MBD family of proteins. All MBD family proteins contain a highly conserved MBD (blue box) in addition to other functional domains. The MBD of
MBD3 has a point mutation (∗) that abolishes methyl-CpG binding. MBD5 and MBD6 do not specifically bind methyl-CpG (lighter blue box). MeCP2, MBD1, and
MBD2 contain C-terminal transcriptional repression domains (TRD) that interact with co-repressor protein complexes (orange box). MBD1 has CxxC-type zinc finger
domains which mediate DNA binding. MBD2 has an N-terminal glycine/arginine rich domain (yellow box) and a C-terminal coiled-coil domain, which is also found in
MBD3 (green box). The functions of MBD4 are mediated through a C-terminal glycosylase domain (red box). Both MBD5 and MBD6 contain proline rich domains
(tan box) while MBD5 has a PWWP motif (purple box) that binds methylated histones.
Human and murine MBD2 and MBD3 have a highly similar
genomic structure, likely indicating the occurrence of an
ancestral gene duplication event (Hendrich and Tweedie, 2003).
Murine MBD2 is encoded by six coding and one non-coding
exons, with the MBD spanning exons 2 and 3, and has three
isoforms: MBD2a, MBD2b, and MBD2c (also known as MBD2t;
Figure 3A; Hendrich and Bird, 1998; Hendrich et al., 1999).
The distinctions between the isoforms of MBD2 correspond
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FIGURE 3 | The isoforms of MBD2 include different functional
domains. (A) The Mbd2 transcript has seven exons, with non-coding regions
(smaller gray box) in exons 1, 6, and 7. Coding regions are contained in exons
1–6 (white and filled boxes). The MBD (blue box) is split between exons 2 and
3 with the glycine/arginine rich region (yellow box) in exon 1. There are two
translation start sites corresponding to MBD2a and MBD2b, respectively.
MBD2c includes an alternatively spliced exon (striped box) between exons 2
and 3. (B) MBD2a utilizes the first translation start site and includes the G/R
rich domain, MBD and C-terminal TRD. Translation of MBD2b excludes the
N-terminal G/R rich domain. MBD2c includes the alternatively spliced exon
and does not contain the C-terminal TRD.
to different functions and binding partners, and are therefore
critical for the understanding of MBD2 function in vivo. All
MBD2 isoforms contain the MBD, which binds specifically to
mCG with no demonstrated affinity for unmodified cytosine,
hmC, or mCH (Hashimoto et al., 2012a; Spruijt et al., 2013).
MBD2a and MBD2b arise from two alternative translation
start sites and differ only in the inclusion of a GR-rich N-terminal
domain in MBD2a (Figure 3B). Both isoforms contain the
full MBD and C-terminal TRD, which is essential for MBD2
interactions with co-repressor protein complexes, including the
NuRD complex (Boeke et al., 2000). The inclusion of the
GR-rich domain in MBD2a may have important functional
consequences, as post-translational methylation of this region
affects interactions with DNA and NuRD (Tan and Nakielny,
2006). MBD2a protein consistently appears as a doublet in
western blot analyses, suggesting that a fourth alternatively
spliced, translated, or cleaved isoform may be present (Ng et al.,
1999; Wood et al., 2016). The C-terminal TRD region of MBD2
includes two domains that interact with different members of
the NuRD complex (Feng and Zhang, 2001; Gnanapragasam
et al., 2011; Desai et al., 2015). The third isoform, MBD2c
or MBD2t, utilizes an alternative third exon and produces a
truncated protein that includes the N-terminal GR-rich domain
and the MBD, without the C-terminal TRD (Figure 3B; Hendrich
and Bird, 1998). This isoform is expressed exclusively in the testes
and ESCs and does not interact with the NuRD complex, with
important functional consequences particularly for pluripotent
stem cells (Hendrich and Bird, 1998; Baubec et al., 2013; Lu et al.,
2014).
MBD2 and NuRD
The composition and functions of the NuRD complex, including
MBD2, are conserved from mammals to other vertebrates and
insects (Wade et al., 1999; Marhold et al., 2004). NuRD consists
of the ATP-dependent remodeling enzymes CHD3/4, histone
deacetylases HDAC1/2, histone chaperones RBBP4/7, and DNA
binding proteins GATAD2A/B and MTA1/2/3 in addition to
MBD2 and MBD3, and has both ATP-dependent nucleosome
remodeling and histone deacetylase activity (Torchy et al.,
2015). Early studies of MBD2 protein function focused on the
transcriptional repressive activities of NuRD and were based on
reporter assay in cultured cells. The first model of MBD2 function
proposed that MBD2 recruits NuRD to methylated regions of the
genome to induce histone deacetylase-dependent transcriptional
silencing and chromatin compaction (Figure 4A; Ng et al., 1999).
In this simplified model, reduced mCG density corresponds to
less MBD2/NuRD binding activity, increased histone acetylation,
and more open chromatin allowing for active transcription
(Figure 4B). This mechanism was observed in numerous studies
in cultured cells examining repression of methylated reporter
constructs and endogenous methylated promoters of several
genes, particularly those related to cancer (Ng et al., 1999; Feng
and Zhang, 2001; Auriol et al., 2005; Chatagnon et al., 2009;
Ramírez et al., 2012).
Despite the many studies of MBD2 as a transcriptional
repressor, it has been challenging to identify specific methylated
genes that are directly targeted for regulation by MBD2 when
studying transcriptome changes on a genome-wide scale. By
correlating MBD2 binding sites determined by chromatin
FIGURE 4 | Simplified model of transcriptional regulation by MBD2 and
NuRD. (A) MBD2 binds to mCG-dense regions as a component of the NuRD
complex, which induces histone deacetylation and chromatin compaction
(large arrows) leading to transcriptional silencing. (B) At transcriptionally active
sites, MBD2/NuRD is replaced by histone acetyltransferases and activating
transcription factors to induce histone acetylation and open, active chromatin.
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immunoprecipitation (ChIP) with differentially expressed genes
upon knockdown of MBD2 in heterologous cells, several studies
support the model that loss of MBD2 primarily results in de-
repression of lowly expressed genes (Günther et al., 2013; Devailly
et al., 2015). However, both upregulation and downregulation
of many genes occurs upon loss of MBD2 in these cell
cultures (Günther et al., 2013; Stefanska et al., 2013). It was
proposed that loss of MBD2 may affect NuRD recruitment,
thus leading to alteration of gene transcription (Reynolds et al.,
2013).
One possible explanation for the subtle gene regulation by
MBD2 is that the interactions between MBD2 and NuRD are
more complicated than originally realized. This may be due
to the presence of different isoforms of MBD2, of which only
two interact with NuRD, and/or post-translational modifications
of MBD2, which can also affect NuRD recruitment (Tan and
Nakielny, 2006; Baubec et al., 2013). Recent findings are in
opposition to the original model which proposed that MBD2
recruits NuRD to methylated sites (Ng et al., 1999). Surprisingly,
NuRD shows less than expected co-occupancy with MBD2 at
methylated genomic regions (Figure 5A). MBD2 is also found at
unmethylated, actively transcribed genes and requires interaction
with the NuRD complex for this localization. These findings
suggest NuRD is recruiting MBD2 to unmethylated sites where it
would otherwise not bind (Figure 5B). It is plausible that MBD2b,
which has the C-terminal TRD, interacts with NuRD and DNA
in a similar manner to MBD2a regardless of DNA methylation,
but this has not been shown directly (Figures 5C,D). In contrast,
MBD2c, which does not interact with NuRD due to the absence
of the TRD, may still bind methylated sites without NuRD
but is absent from unmethylated sites (Figures 5E,F). These
findings support the view that MBD2, through its interactions
FIGURE 5 | Different DNA binding and NuRD interactions of MBD2
isoforms. (A) MBD2a binds to methyl-CpG dense sites with the NuRD
complex. (B) At unmethylated sites, MBD2 recruitment to DNA is dependent
on interactions with NuRD through the C-terminal TRD. (C) Similarly to
MBD2a, MBD2b binds to methyl-CpG dense sites with NuRD and may be
recruited to unmethylated sites via interaction with NuRD (D). MBD2c lacks
the C-terminal TRD and does not interact with NuRD. Therefore, MBD2c may
bind methylated sites without NuRD (E) and, in this model, would not be
recruited to unmethylated sites by NuRD (F).
with NuRD, may be involved in transcriptional activation as well
as repression, and may be localized at unmethylated sites (Baubec
et al., 2013).
The other critical factor that may be affecting MBD2 function
is the role of MBD3 in complex with NuRD. MBD3 has repressive
activity as part of the NuRD complex, despite not binding to
mCG (Wade et al., 1999), but its exact functions within NuRD
and the mechanisms and implications of NuRD assembly with
either MBD2 or MBD3 are unknown. Several studies gave strong
indication that MBD2 and MBD3 have distinct functions with
NuRD in vivo. First, NuRD incorporates MBD2 or MBD3 into
mutually exclusive complexes (Le Guezennec et al., 2006) and
second, genetic knockout studies in mice show distinctly different
phenotypes for each gene (Hendrich et al., 2001). It is also clear
that MBD2/NuRD and MBD3/NuRD have distinct genome-wide
distributions, reflecting their different DNA-binding properties,
and different functions, particularly in ESCs (Kaji et al., 2006;
Gu et al., 2011; Baubec et al., 2013; Günther et al., 2013; Lu
et al., 2014). Together these findings suggest that transcriptional
regulation by MBD2 is more dynamic and multifaceted than
originally proposed, and this may help explain why direct
targets of MBD2 have been difficult to identify. Further work is
required to determine the dynamics of MBD2, MBD3, and NuRD
recruitment to chromatin, and how MBD2 may function within
and independently of NuRD.
MBD2 and Other Protein Complex
Interactions
Although MBD2 is usually associated with the NuRD co-
repressor complex, there is increasing evidence that MBD2
functions may rely on interactions with several other diverse
protein complexes. Several of these interactions directly affect
MBD2 binding to NuRD, and it is possible that they also mediate
NuRD-independent functions. The most well-described example
is the post-translational methylation of MBD2 by PRMT1
and PRMT5 (Le Guezennec et al., 2006; Tan and Nakielny,
2006). Methylation of the N-terminal RG-rich region of MBD2a
(Figures 6A,B), and presumably MBD2c, although this has
not been shown directly (Figures 6C,D), reduces the affinity
of MBD2 for the NuRD complex and for methylated DNA.
Importantly, these interaction may represent an MBD2-specific
mechanism to regulate the formation or function of the NuRD
complex, as MBD3/NuRD does not interact with the PRMT
proteins (Le Guezennec et al., 2006). Methylation of histone
H4 by PRMT1 or PRMT5 produces transcriptionally active or
repressed chromatin, respectively (Nicholson et al., 2009). It
is unknown if PRMT chromatin-modifying activity is affected
by MBD2 interactions. For example, PRMT may be guided to
methylate H4 where MBD2/NuRD is localized, or these functions
may be independent of each other.
There is also surprising evidence that MBD2 is required for
active transcription in several contexts, including at least two
genes that are silenced by mCG (Wang et al., 2013; Weaver et al.,
2014). Further studies in cultured cells showed that MBD2 can
form a complex with TACC3 and the histone acetyltransferase
pCAF to activate transcription (Angrisano et al., 2006).
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FIGURE 6 | DNA binding dynamics of MBD2 isoforms depend on
post-translational modifications. (A) MBD2a and NuRD binding to
methylated sites results in nucleosome remodeling (thick arrows) and
deacetylation (red triangles), producing transcriptional silencing.
(B) Post-translational methylation of the N-terminal glycine/arginine rich region
of MBD2a by PRMT1/5 reduces the affinity of MBD2a for NuRD and
methylated DNA and may not produce transcriptional repression. (C) MBD2c
does not interact with the NuRD complex but does bind methylated DNA. It is
not fully understood how this binding may affect transcriptional regulation.
(D) MBD2c has the N-terminal G/R rich domain, but it is not clear if it is also
methylated by PRMT1/5 and if this modification would affect DNA binding
similarly to MBD2a.
Additionally, MBD2a, but not MBD2b, reactivates transcription
of unmethylated, cAMP-responsive genes through interactions
with RNA helicase A, part of the CREB transcriptional
coactivator complex (Fujita et al., 2003). An intriguing finding
from both of these studies is that when MBD2 is associated with
either of these protein complexes, it is not bound to histone
deacetylases, which are key components of the NuRD complex.
It is not clear if these interactions represent additional NuRD-
independent functions of MBD2, or if they only serve to mediate
MBD2-NuRD interactions.
Further work is necessary to resolve the many remaining
questions surrounding the mechanisms of MBD2 function both
in association with and independent of the NuRD complex.
The majority of studies on MBD2 protein complex interactions
have been performed in cell culture systems, and there is
little information on these mechanisms in a relevant biological
context. A mouse with biochemically tagged endogenous MBD2
that was recently described could be used to address these
questions in vivo (Wood et al., 2016).
Genome-Wide Binding Patterns and
Transcriptional Regulation
The binding of MBD2 to methylated DNA depends on the
presence of an intact MBD (Baubec et al., 2013). Several studies
have examined MBD2 binding to specific loci such as the
methylated regulatory regions of BRCA1 or Foxp3 (Auriol et al.,
2005; Wang et al., 2013), but only a few attempts have been made
to determine the genome-wide distribution of MBD2. These
experiments are complicated by the fact that DNA methylation
patterns are dynamic and cell-type specific (Schultz et al.,
2015) and reliable antibodies to MBD2 are limited; therefore
all ChIP data to date have been acquired using cultured cells
or biochemical tagging approaches. These studies in HeLa cells
(Chatagnon et al., 2011; Günther et al., 2013), mouse ESCs
(Baubec et al., 2013), and breast cancer cell lines (Menafra et al.,
2014; Devailly et al., 2015) all showed that MBD2 is broadly
associated with densely methylated genomic regions, with no
detectable sequence specificity. These studies found MBD2 is
enriched at transcription start sites, promoters, and exons that
coincide with methylated CGIs. Highly methylated sites that
have low mCG density, such as most repetitive regions and low-
CpG promoters, introns and intergenic regions, show low or no
enrichment for MBD2 (Baubec et al., 2013; Günther et al., 2013;
Menafra et al., 2014).
Surprisingly, MBD2 was also detected at certain unmethylated
sites including intermediate- and high-CpG promoters that
correlate with the presence of activating histone marks. It is
currently unclear what proportion of cellular MBD2 is localized
at these sites, as opposed to methylation-dense regions of the
genome. These distribution patterns may in fact be different
localization of different MBD2 isoforms. The MBD2c isoform,
which lacks the C-terminal region that interacts with NuRD, was
lost from these regions but retained at methylated sites, which
suggests that MBD2 localization to unmethylated sites is NuRD-
dependent. MBD2 binding to unmethylated promoters is also
associated with tissue-specific regulatory regions and low levels
of gene expression (Baubec et al., 2013; Günther et al., 2013;
Menafra et al., 2014). In contrast, MBD3 binding, similar to
NuRD, is not correlated with methylation and instead is enriched
at transcriptionally active, open chromatin regions (Baubec et al.,
2013; Günther et al., 2013). Despite evidence from several studies
that MBD2/NuRD and MBD3/NuRD are localized at active
chromatin, biochemical evidence shows that NuRD is repelled
by the activating histone mark H3K4me3 (Eberl et al., 2013).
Therefore, the mechanisms of MBD2/NuRD recruitment and
distribution on chromatin remain to be further investigated.
Additionally, the dynamics and biological consequences of NuRD
formation with either MBD2 or MBD3 are unclear, particularly
in vivo in the cellular context. It is also essential to recognize that
to date all studies of MBD2 genome-wide localization have been
performed in cultured cells. A mouse expressing a tagged allele
of MBD2 (Wood et al., 2016) could be utilized to perform ChIP-
seq in various cell types to explore these questions in an in vivo
setting.
MBD2 BIOLOGICAL FUNCTIONS
Neuronal Functions of MBD2 in Context
of Related MBD Proteins
Epigenetic mechanisms in the brain are distinct because
DNA methylation changes dynamically throughout development
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and in learning and memory processes (Lister et al., 2013;
Heyward and Sweatt, 2015). The highly complex network of
diverse neuronal subtypes each have distinct epigenomic and
transcriptional profiles (Mo et al., 2015), further suggesting
that epigenetic regulation is essential for the maintenance
and function of the brain. Most MBD proteins are associated
with neuronal functions in both humans and mice. The
most well-studied example is MECP2, which when mutated,
deleted, or duplicated causes the neurodevelopmental disorder
Rett syndrome (Amir et al., 1999). Loss of MBD5 is the
causative factor in 2q23.1 microdeletion syndrome, characterized
by intellectual disability, behavioral problems and seizures
(Talkowski et al., 2011). Mutations in the other MBD proteins
have been correlatively linked to autism spectrum disorder (ASD;
Li et al., 2005; Cukier et al., 2010, 2012). Mouse models with
deletion of Mecp2 or Mbd5 closely recapitulate the symptoms
of the respective human disorders, reflecting the conserved
functions of these proteins (Guy et al., 2001; Camarena et al.,
2014). Mutations in Mbd1 in mice affect adult neurogenesis and
result in behavioral changes considered to be representative of
ASDs in humans (Zhao et al., 2003; Allan et al., 2008). A Mbd3
brain-specific conditional null mouse has defects in cortical
thickness and neuronal differentiation and is neonatal lethal
(Knock et al., 2015).
With this evidence, it is surprising that Mbd2 null mice show
only mild phenotypes, including deficits in pup nurturing and
nesting behaviors, hypoactivity, and low body weight (Hendrich
et al., 2001; Wood et al., 2016). There are several possible
interpretations of these findings. First, MBD2 may be dispensable
for brain function, unlike most other MBD proteins that are
clearly required. Alternatively, it is possible that loss of MBD2
does impair neuronal functions, but in too small a population of
cells to produce robust changes in behavior. For example, Mbd2
null mice have changes in the proliferation and differentiation of
olfactory receptor neurons without notable changes in olfactory-
dependent behaviors (Macdonald et al., 2010; Wood et al.,
2016).
Another model commonly put forth is that MBD2 functions
in the brain are at least partially redundant with other MBD
proteins, which may be compensating for the loss of MBD2 at
the cellular or systemic level. The most likely candidates for
compensation are MeCP2, which is abundant in the brain but
has quite different molecular functions to MBD2 (Du et al.,
2015), or MBD3, as an alternate member of the NuRD complex
(Le Guezennec et al., 2006). However, recent investigations into
the spatiotemporal expression patterns of the MBD proteins
showed that MBD3 is most highly and selectively expressed in the
brain at younger ages in mice, and lowly expressed in the adult
brain. In contrast, MBD2 shows consistent expression during
development in multiple tissues, particularly the lung, liver, and
colon (Figure 7; Wood et al., 2016). This evidence suggests
that, at least in the adult brain, MeCP2 may be the dominant
methylation ‘reader’ protein because MBD1 and MBD3 are lowly
expressed while MBD2 appears to be dispensable for brain
function. However, this scenario would also necessarily indicate
that any NuRD-independent functions specific to MBD2, but not
MBD3, are also dispensable for brain function.
A recent study revealed a function for MBD2 in the
hippocampus that may underlie the maternal nurturing
phenotypes in the Mbd2 null mouse (Hendrich et al., 2001;
Weaver et al., 2014). This study found that MBD2 expression is
upregulated in response to maternal licking and grooming and
was required for upregulation of the glucocorticoid receptor (GR)
gene in the hippocampus (Weaver et al., 2014). Hippocampal GR
signaling affects the regulation of stress and maternal nurturing
behaviors through the hypothalamic–pituitary–adrenal (HPA)
axis (Liu et al., 1997). According to this model, a female Mbd2
null mouse born to a heterozygous mother would have an
attenuated GR expression response to maternal behavior, leading
to long-term epigenetic changes at the GR locus. These epigenetic
changes could in turn affect this Mbd2 null female mouse’s own
maternal nurturing behaviors, as has been observed in female
rats whose dams were exposed to environmental stress (Liu et al.,
1997; Francis et al., 1999; Weaver et al., 2004). GR signaling has
widespread, systemic effects related to stress, metabolism and
inflammation (Kadmiel and Cidlowski, 2013), but it is unknown
if loss of MBD2 affects these signaling mechanisms outside the
hippocampus.
Isoform-Specific Roles in Pluripotent
Cells
The maintenance, proliferation, and differentiation of
pluripotent cells are highly dependent on epigenetic mechanisms
(Meissner, 2010). It is clear that MBD3 has an essential role in
pluripotent ESCs because Mbd3 null mice are early embryonic
lethal (Hendrich et al., 2001). In contrast, mice with loss of any
other MBD protein are viable, albeit with a range of phenotypic
severity (Du et al., 2015). Recent work has revealed an important
role for MBD2 in pluripotent cells. MBD2 is more lowly
expressed in ESCs compared to MBD3 (Lu et al., 2014) and
was initially thought to repress reprogramming of somatic to
induced pluripotent stem (iPS) cells (Lee et al., 2013). However,
further efforts found that differentially spliced isoforms of
MBD2 actually have a role in both repression and promotion
of reprogramming to pluripotency in human pluripotent stem
cells (hPSCs; Lu et al., 2014). MBD2a, the longest isoform that
includes both the N-terminal GR-rich domain and C-terminal
TRD, is specifically enriched in differentiated fibroblasts (DFs)
while alternatively spliced MBD2c, which lacks the TRD, is
enriched in hPSCs. Overexpression of MBD2a in hPSCs disrupts
pluripotency, presumably by mediating NuRD targeting to the
OCT4 and NANOG promoter regions and down-regulating
their expression. In contrast, MBD2c is also bound at these
promoters but does not interact with NuRD. Overexpression
of MBD2c together with other reprogramming factors in
DFs actually enhances the reprogramming efficiency. The
authors conclude that MBD2a and MBD2c mediate the balance
between proliferation and differentiation of hPSCs (Lu et al.,
2014).
It is unclear why Mbd2 constitutive null mice are viable and
fertile when there is a role for MBD2 and NuRD in pluripotent
cells (Hendrich et al., 2001; Reynolds et al., 2012; Lu et al., 2014).
Similarly to the brain, it is possible that MBD3 may be sufficient to
Frontiers in Genetics | www.frontiersin.org 7 May 2016 | Volume 7 | Article 93
fgene-07-00093 May 24, 2016 Time: 12:31 # 8
Wood and Zhou MBD2 Molecular and Biological Functions
FIGURE 7 | Summary of MeCP2, MBD1, MBD2, and MBD3 spatiotemporal expression patterns. MBD2 is expressed throughout the body with lower relative
expression in the brain compared to other MBD proteins at postnatal day 7 (P7) and postnatal day 42 (P42). MBD2 is also up regulated temporally in the adult spleen
and small intestine. In contrast, MeCP2 is most highly expressed in the brain. MBD1 and MBD3 are highly expressed in the brain at early ages, but down regulated in
the adult brain. Adapted from Wood et al. (2016).
mediate NuRD-related functions in the absence of MBD2 during
embryogenesis. However, a genetic interaction between Mbd2
and Mbd3 argues that MBD3 cannot fully compensate for the loss
of MBD2 (Hendrich et al., 2001) and further studies are needed
to resolve this question.
Emerging Roles for MBD2 in Immunity
There is strong evidence that DNA methylation and other
epigenetic mechanisms are essential in hematopoiesis and
differentiation of myeloid and lymphoid cell lineages (Álvarez-
Errico et al., 2014; Shih et al., 2014). NuRD, MBD2, and MBD3
have roles in multiple cell populations (Dege and Hagman, 2014).
For example, the core NuRD component CHD4 is required
for the maintenance and differentiation of hematopoietic stem
cells (Yoshida et al., 2008). MBD2 is the only MBD protein
among MeCP2, MBD1, and MBD3 that is expressed highly in the
spleen, a site for induction of both innate and adaptive immune
responses. Intriguingly, MBD2 is upregulated temporally in the
adult spleen and not detectable at younger ages (Figure 7; Wood
et al., 2016).
A specific role for MBD2 in early hematopoietic stem cells and
other progenitor cells has not been described. Mbd2 null mice
have unaltered lymphoid organs and major lymphocyte subsets,
suggesting that MBD2 may not be required at the early stages
of hematopoiesis (Hutchins et al., 2002). In B cells, the NuRD
complex interacts with various transcription factors to mediate
temporal changes in development and differentiation (Gao et al.,
2009; Musselman et al., 2012). Transcriptional regulation of the
B-cell specific Cd79a gene involves MBD2-dependent CHD4
recruitment, but whether B cells are broadly affected in Mbd2 null
mice is unknown (Ramírez et al., 2012).
The functions of NuRD and MBD2 in several T cell
populations have been studied more extensively. Loss of MBD2
has been linked to changes in proliferation or maturation of
multiple T cell populations. These changes may arise from altered
expression of several critical factors, some of which are controlled
by differentially methylated regulatory regions. For example,
loss of MBD2 or loss of NuRD components CHD4 or MTA2
skews CD4+ T cell polarization toward Th2 populations, with
implications for pathogen resistance (Hutchins et al., 2002, 2005;
Lu et al., 2008; Hosokawa et al., 2013). One study proposed
that these changes may occur because MBD2/NuRD regulates
expression of the Th2 cytokine locus, which is demethylated
during Th2 cell differentiation (Aoki et al., 2009). Interestingly,
MBD2 also indirectly affects CD4+ T cell maturation by
regulating gene expression programs in dendritic cells, which are
required to direct T helper cell maturation (Cook et al., 2015).
The maturation of CD8+ T cell populations into effector and
memory cells after acute viral infection is also directly affected
by loss of MBD2, consistent with MBD2 regulating expression
of surface markers and cytokines (Kersh, 2006). Finally, several
studies found MBD2 regulates the expression of the master
Treg cell transcription factor Foxp3 (Lal et al., 2009; Wang
et al., 2013). MBD2 binds to a Treg-specific demethylation
region (TSDR) upstream of Foxp3 that becomes demethylated
in thymus-derived natural Tregs. MBD2 promotes the TET2-
mediated demethylation of the TSDR in Treg cells. Consequently,
Mbd2 null mice show decreased Treg numbers and impaired Treg
suppressive function in addition to retaining methylation at the
TSDR (Wang et al., 2013).
Disruptions to the NuRD complex are detrimental to
immunity, as evidenced by a study that showed mice with
loss of MTA2 develop a severe lupus-like autoimmune disease
(Lu et al., 2008). Although loss of MBD2 results in reduced
numbers of Treg cells, Mbd2 null mice surprisingly do not
develop autoimmunity, perhaps because their T effector cells
are less responsive to stimulation and more susceptible to Treg
suppression (Wang et al., 2013). In fact, loss of MBD2 is
protective against experimental autoimmune encephalomyelitis,
a model of T cell mediated autoimmunity and demyelinating
diseases of the central nervous system (Zhong et al., 2014).
In human patients, increased levels of MBD2 and global
demethylation in CD4+ T cells has been observed in several
autoimmune disorders, including systemic lupus erythematosus
(Balada et al., 2007; Liu et al., 2011), systemic sclerosis,
dermatomyositis (Lei et al., 2009) and MBD2 was determined
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to be a susceptibility locus for psoriasis (Tsoi et al., 2012).
These human and mouse studies point to MBD2/NuRD being
an essential regulator of immune function with therapeutic
potential. However, considerable effort is required to fully
understand the complexities of MBD2 function in immunity at
the cellular and systemic levels.
Implications for the Role of MBD2 in
Cancer
Epigenetic factors have been studied extensively in regards
to cancer initiation, progression, and treatments (Baylin and
Jones, 2011). The NuRD complex may affect tumorigenesis
by modifying expression or activities of transcription factors
linked to cancer, silencing hypermethylated tumor suppressor
genes, and/or maintaining genomic stability (Lai and Wade,
2011). Many studies have attempted to link loss of MBD2 or
MBD3 to significantly increased cancer predisposition in human
patients, but evidence for this is limited. Therefore, the focus
of studies on MBD2 and MBD3 in cancer has shifted to their
potential as therapeutic targets. However, concerns have been
raised regarding the feasibility of directly targeting these proteins
and possible off-target effects (Parry and Clarke, 2011).
MBD2 has been studied particularly in the context of
colorectal cancer, but questions remain as to the specific role of
MBD2 in tumor initiation or progression. Interestingly, the colon
is the only tissue besides the brain to show notable co-expression
of MeCP2, MBD1, MBD2, and MBD3, suggesting the reading
of mCG may be particularly important in this tissue (Figure 7;
Wood et al., 2016). MBD2 is required for regulation of gene
expression in the gastrointestinal tract, as Mbd2 null mice show
altered spatial expression of several genes in the small intestine
and colon (Berger et al., 2007). Loss of MBD2 is protective against
tumorigenesis specifically in ApcMin/+ mice, a mouse model of
sporadic colorectal tumorigenesis (Sansom et al., 2003). The
ApcMin/+mouse develops tumors due to significantly upregulated
Wnt signaling (Sansom, 2004), which is downregulated in the
absence of MBD2 (Phesse et al., 2008).
While these results suggest targeting MBD2 may have
therapeutic potential for colorectal cancer, further investigations
show that the downregulation of Wnt signaling may be
attributed to general disruption of chromatin regulation rather
than MBD2-specific functions. First, Mbd2 null mice in a
wild-type background do not show significant changes in
intestinal histology or Wnt signaling (Phesse et al., 2008).
More importantly, similar downregulation of Wnt signaling
and reduced tumorigenesis occurs when perturbing several
other chromatin binding or modifying factors, including the
DNMTs (Cai et al., 2014), the methylation-binding protein Kaiso
(Prokhortchouk et al., 2006), and the chromatin remodeling
factor Brg1 (Holik et al., 2014). In contrast, MBD3 is more likely
to have a direct function in the gastrointestinal tract. Loss of
MBD3 specifically in the gut results in increased tumorigenesis
induced by inflammation through the upregulation of targets
of the AP-1 transcription factor (Aguilera et al., 2011). It is
currently unknown if these pathways are also affected by loss of
MBD2.
Loss of MBD2 has complex effects on gene expression with
both upregulation and downregulation of many genes, which
differentially affects tumorigenesis in various mouse cancer cell
lines and in human cancer cell xenografts in mice (Campbell
et al., 2004; Stefanska et al., 2013; Devailly et al., 2015). One
way this could occur is MBD2 binding to hypermethylated
promoters of tumor suppressor genes and contributing to their
transcriptional silencing, which has been shown to occur in
multiple human cancer cell lines (Lopez-Serra et al., 2008).
Therefore, loss of MBD2 may be protective against tumorigenesis
by relieving transcriptional repression of hypermethylated tumor
suppressor genes such as p14(ARF) and p16(INK4A) that
commonly show aberrant methylation in colon cancer cells
(Magdinier and Wolffe, 2001; Martin et al., 2008). Similar
mechanisms have been observed in glioma cells (Zhu et al., 2011)
and breast cancer cells (Mian et al., 2011).
Conversely, downregulation of certain genes in the absence of
MBD2 may be protective against tumorigenesis. MBD2 has been
shown to directly repress human telomerase reverse transcriptase
(hTERT) in several cancer cell types (Chatagnon et al., 2009).
hTERT is usually hypermethylated and silenced, but is expressed
in most cancer cells and therefore, in regards to this mechanism,
loss of MBD2 may encourage tumor growth. In prostate
cancer cells, loss of MBD2 suppresses tumor growth through
hypermethylation and silencing of pro-metastatic genes (Shukeir
et al., 2006). These complexities indicate that identification and
manipulation of specific therapeutic pathways targeted via MBD2
will be challenging.
Studies of MBD2 in human cancer patients also point to
MBD2 as a potential regulator of tumorigenesis. The finding
that the 18q21 locus that includes MBD2 is deleted in 70% of
human colorectal cancers (Fearon et al., 1990) led to speculation
that MBD2 itself could be a candidate tumor suppressor gene.
However, further investigation showed that only the deleted in
colon cancer (DCC) gene at this locus is likely to be directly
linked to cancer progression. All other neighboring genes,
including MBD2, are rarely affected by hypermethylation or
point mutations in colorectal cancer (Bader et al., 2003; Derks
et al., 2009). MBD3 is also generally unaffected by mutations or
epigenetic changes in colon cancer (Zhu et al., 2004).
Despite the absence of mutations in MBD2 or MBD3 in cancer,
there is evidence that these genes show altered regulation in
tumors. Both MBD2 and MBD3 are downregulated in multiple
human tumor types, but it is not clear what effect this has
on tumor progression (Kanai et al., 1999; Müller-Tidow et al.,
2001; Pontes et al., 2014). Studies of MBD2 in breast cancer
have produced conflicting results. One study found that MBD2
is upregulated in breast tumors (Billard et al., 2002), while
another found no difference (Müller et al., 2003). Analysis of
single nucleotide polymorphisms in MBD2 in breast cancer
patients were similarly difficult to interpret, although some weak
associations were detected (Zhu et al., 2005; Sapkota et al., 2014).
Because MBD2 appears to have variable or context specific effects
on tumorigenesis, significant further investigations into the
molecular mechanisms of MBD2 function must be undertaken
to identify potential therapeutic targets associated with these
functions.
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OUTSTANDING QUESTIONS ON MBD
PROTEIN FUNCTION
An essential goal of the MBD protein field that remains
unresolved is defining the specific functions of these proteins in a
biologically relevant context. The MBD proteins are historically
associated with transcriptional repression, yet attempts to
identify specific methylated loci that are directly regulated and
suppressed by these proteins in vivo do not fully support this
model. Ablation of the MBD proteins, including MeCP2, MBD2,
or MBD3 produces many subtle transcriptional changes without
specific genes consistently showing upregulation, which would be
expected according to models of MBD proteins as transcriptional
repressors with direct targets (Chahrour et al., 2008; Günther
et al., 2013). For MBD2, these questions are challenging to resolve
because it is experimentally difficult to distinguish between
functions that are MBD2-specific rather than mediated by the
NuRD complex as a whole, while the role of MBD3 must
also be considered. Numerous studies have relied on poorly
characterized antibodies to MBD2, or antibodies that do not
discriminate between MBD2 and MBD3. The recently described
genetic tools consisting of mice expressing tagged MBD2 and
MBD1 (Wood et al., 2016) will aid in future investigation of MBD
protein functions in vivo.
One proposed explanation for why transcriptional repression
is generally maintained in single MBD gene null mouse models
is that the MBD family proteins are functionally redundant
(Baubec and Schübeler, 2014). This hypothesis is most applicable
to MBD2 and MBD3, which are very closely related both
in their protein structure and as components of the NuRD
complex (Hendrich and Bird, 1998; Le Guezennec et al.,
2006). However, this model is undermined by the fact that
each MBD protein has distinct loss-of-function phenotypes,
spatiotemporal expression patterns, DNA binding properties, and
protein complex interactions (Du et al., 2015; Wood et al., 2016).
Therefore, the MBD proteins are unlikely to be functionally
interchangeable in vivo.
Genetic evidence shows that loss of each MBD protein
produces distinct phenotypes in mice (Guy et al., 2001; Hendrich
et al., 2001; Allan et al., 2008). Loss of both MBD2 and MeCP2
in mice decreases survivability compared to loss of MeCP2 alone
(Martín Caballero et al., 2009), while loss of MBD2 in Mbd3
heterozygous mice resulted in decreased viability compared
to Mbd3 heterozygous mice with wild-type MBD2 expression
(Hendrich et al., 2001). These findings indicate that MBD2 has
other functions for which MeCP2 and MBD3 are unable to
compensate. There is currently no information on the phenotype
of mice with loss of both Mbd1 and Mbd2, which would
help clarify any potential interactions between these two MBD
proteins. This has been difficult to achieve because the two genes
are less than 4 Mb apart on the same chromosome.
MBD2 also shows a strikingly distinct spatiotemporal
expression pattern at the protein level compared to MeCP2,
MBD1, and MBD3 (Figure 7; Wood et al., 2016). It was shown
that MBD2 has widespread expression, and is the only MBD
protein of this group with detectable protein levels in multiple
tissues. Therefore, MBD2 may have unrealized functions in these
tissues, such as the spleen or small intestine, that may be linked
to other reported functions for MBD2 in immunity and the
gastrointestinal tract (Berger et al., 2007; Cook et al., 2015).
Other molecular and biochemical evidence also suggest that
MBD2 and MBD3 are not functionally interchangeable, despite
their conservation and both being part of the NuRD complex
(Le Guezennec et al., 2006). First, these proteins have entirely
different DNA-binding capabilities, which is reflected in their
distinct genome-wide binding profiles (Hashimoto et al., 2012a;
Baubec et al., 2013; Günther et al., 2013). MBD2 and MBD3
also differ in their interactions with the NuRD complex, which
could result in different context-specific roles (Le Guezennec
et al., 2006; Baubec et al., 2013). Finally, MBD2 has numerous
specific interactions with other protein complexes that influence
how MBD2 interacts with NuRD (Angrisano et al., 2006; Tan and
Nakielny, 2006). It is not clear if these other binding partners
represent specific, NuRD-independent functions of MBD2, or
if they serve to mediate the interactions between MBD2 and
NuRD.
There are also many unanswered questions regarding the
in vivo dynamics of the NuRD complex and MBD2 or MBD3.
Biochemical evidence has shown that MBD2 and MBD3 are
mutually exclusive in the NuRD complex and that the presence
of the MBD protein is necessary for NuRD complex formation
and function (Saito and Ishikawa, 2002; Le Guezennec et al., 2006;
Ramírez et al., 2012). The spatiotemporal expression patterns of
MBD2 and MBD3 raise further questions about NuRD formation
and function, particularly in adult tissues where MBD3 is nearly
undetectable but MBD2 is highly expressed (Figure 7; Wood
et al., 2016). These findings may indicate that the NuRD complex
necessarily forms with MBD2 in most peripheral adult tissues
in vivo where MBD3 is absent or lowly expressed. Alternatively,
the abundance of MBD2 over MBD3 may be indicative of
other NuRD-independent MBD2 functions. With this model, it
remains to be determined why loss of MBD3, even conditionally
in specific tissues, has severe phenotypic consequences, while
constitutive loss of MBD2 has only mild effects (Hendrich et al.,
2001; Aguilera et al., 2011; Knock et al., 2015; Wood et al., 2016).
One possible model for MBD2, MBD3, and NuRD
interactions is that MBD3 is essential for NuRD formation
and function, while MBD2 represents a more transient member
of NuRD that is required to fine-tune NuRD function and
thus may be expendable. One study determined that most
NuRD complexes in mammalian cells contain MBD3 rather
than MBD2 (Zhang et al., 1999), but the dynamics of these
interactions in vivo have not been fully determined. This scenario
is supported by the distinct functions of MBD2 and MBD3 in
ESCs. MBD3 is absolutely required for embryogenesis, while
complete ablation of MBD2 does not compromise survivability
or fertility (Hendrich et al., 2001). In contrast, different isoforms
of MBD2 differentially regulate NuRD activity in ESCs (Lu et al.,
2014). Genetic studies on MBD2 and MBD3 in the brain show a
similar pattern, in which brain-specific loss of MBD3 is neonatal
lethal, while loss of MBD2 does not severely impair brain
functions (Knock et al., 2015; Wood et al., 2016). Additional
biochemical evidence is necessary to determine if misregulation
of NuRD activity occurs upon loss of MBD2 in the brain.
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The different isoforms of MBD2 introduce further
complications into models of MBD2/NuRD function. With a few
important exceptions, most studies of MBD2 do not acknowledge
or distinguish between the multiple alternatively spliced or
translated isoforms. New evidence shows that experimentally
distinguishing between the different isoforms of MBD2 may
be essential to understanding this protein’s different functions
in vivo. A recent study described opposing functions for MBD2a
and MBD2c isoforms in the differentiation or proliferation
of ESCs (Lu et al., 2014). Biochemical evidence shows that
MBD2a, MBD2b, and MBD2c have different interactions
with NuRD and other protein complexes and are recruited
to DNA differently (Tan and Nakielny, 2006; Baubec et al.,
2013; Lu et al., 2014). These multiple isoforms of MBD2
may differentially regulate NuRD activity in other cell types
besides ESCs through mechanisms that have yet to be fully
explored. Therefore, while complete deletion of MBD2 does
not have severe phenotypic effects, it is possible that disrupting
the balance of MBD2 isoform expression could be more
detrimental to NuRD regulation and therefore produce more
robust phenotypes.
In summary, MBD2 is an integral part of the NuRD complex
with many unanswered questions regarding its molecular and
biological functions. In order to address these questions, it is
essential to unravel the complexities of different isoforms of
MBD2 in association with NuRD. The three isoforms of MBD2
each have different interactions with NuRD and other protein
complexes, which may contribute to their distinct functions.
In addition, MBD2 activity must be considered in the context
of MBD3 and NuRD, especially in vivo where MBD2 and
MBD3 have distinct spatiotemporal expression patterns. These
complex isoforms and interactions may underlie the surprisingly
mild phenotype of Mbd2 knockout mice. Future investigations
into MBD2 functions may have important implications for
the study of pluripotency, immunity, and cancer, in addition
to revealing insights into broader epigenetic mechanisms. The
recent development of tagged MBD2 knockin mice provides a
powerful tool to address these questions through future in vivo
mechanistic studies (Wood et al., 2016).
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